Report: Compumedics FY19 Results Deliver Record Revenue & Solid Growth

Posted on September 2nd, by Bourse Communications in News and Announcements. Comments Off on Report: Compumedics FY19 Results Deliver Record Revenue & Solid Growth


  • Record revenues from shipped and invoiced sales were $41.5m for FY19, up 12% on FY18 ($37m)
  • EBITDA increased 40% to $5.9m for FY19, compared to $4.2m for FY18
  • NPAT increased 43% to $4.0m for FY19, compared to $2.8m for FY18
  • Record core business sales orders taken of $40.5m in FY19 up 7.5% compared to FY18
  • Cash on hand increased to $4.6m at 30 June 2019 compared to $3.9m at 30 June 2018


  • Core business:

– Growth across key markets and the further partial booking of the first MEG sale drives profitability higher in FY19
– Growth in Asian sales and the DWL business in Germany, the USA and other regions

  • eHealth:

-The NeXus 360 platform is generating a minimum of A$660K revenue per annum with total signed contract value exceeding A$1m in annual subscription fees
– Compumedics is poised for strong growth in both the sleep and neurodiagnostic eHealth markets due to Nexus 360 USA and Australia market penetration and continued development of the SomFit technology

  • Neuroscan/MEG:

– Market expansion continuing with first major MEG contract initial phase undertaken
– Additional new MEG sales being actively pursued

  • FY20 guidance, excluding additional MEG sales:

– Sales $42m-$44m, EBITDA $6.5m-$7.5m, NPAT $4.0m-$5.0m

Compumedics Limited (ASX: CMP) (“Compumedics” or “Company”) wishes to announce its financial results for the full-year ending 30 June 2019 (FY19).

Compumedics’ net profit after tax increased 43% in FY19 to $4.0m, compared to $2.8m in full-year 2018 (FY18). EBITDA for FY19 was $5.9m, an improvement of 40%, compared to $4.2m in FY18. Shipped and invoiced sales increased 12% to a record $41.5m for FY19, compared to $37m for FY18. The Company took new record sales orders in FY19 of $40.5m, up 7.5% from new orders taken in FY18, excluding MEG.

Earnings improved as a result of the increased sales in China, Germany-based DWL and the USA all posting growth over the prior year. The Company also booked a further partial amount for the sale of its first MEG system, as the first phase of the installation has been undertaken.

Compumedics’ full Business Update and FY19 financial results can be accessed here.

For further information please contact:
Rod North, Managing Director,
Bourse Communications Pty Ltd
T: +61 3 9510 8309, M: 0408 670 706
E: [email protected]

About Compumedics Limited
Compumedics Limited (ASX: CMP) is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe and the Middle East.
Executive Chairman Dr David Burton founded Compumedics in 1987. In the same year the company successfully designed and installed the first Australian, fully computerised sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets.
Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian governments.

Comments are closed.